Gastric Cancer: A deep learning model predicts the efficacy of neoadjuvant chemotherapy for advanced gastric cancer

Gastric cancer is a common malignant tumor originating from the epithelial epithelium of the gastric mucosa, its early symptoms are insidious and non-specific, often similar to the symptoms of chronic diseases such as gastritis and gastric ulcers, and are easily ignored, resulting in 80%-90% of gastric cancer patients being advanced when they are first diagnosed
.

In recent years, neoadjuvant chemotherapy has achieved certain effects in improving the prognosis of patients with advanced gastric cancer, which is accepted
by surgeons and patients.

In the early stage, Gao Xin's team from the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, together with Shanxi Provincial Cancer Hospital, proposed for the first time a predictive method for predicting
the efficacy of neoadjuvant chemotherapy for advanced gastric cancer based on artificial intelligence.

Figure 1 Flow of new methods for predicting the efficacy of neoadjuvant chemotherapy for advanced gastric cancer

Figure 2 Visualization of the efficacy prediction model of neoadjuvant chemotherapy for advanced gastric cancer

The results show that the constructed model has high accuracy and strong generalization, and the prediction accuracy is greater than 0.

The results were published in Gastric Cancer
.

Original Source:

Zhang J, Cui Y, Wei K, Li Z, Li D, Song R, Ren J, Gao X, Yang X.